Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jul;74(2):318–322. doi: 10.1038/bjc.1996.360

A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.

D C Linch 1, B Vaughan Hudson 1, B W Hancock 1, P J Hoskin 1, D C Cunningham 1, A C Newland 1, D W Milligan 1, P A Stevenson 1, J K Wood 1, K A MacLennan 1, L Anderson 1, W M Gregory 1, G Vaughan Hudson 1
PMCID: PMC2074593  PMID: 8688344

Abstract

A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin's lymphomas for over 20 years, but several newer regimens, referred to as second or third generation, have been reported to give improved results in single-centre studies. Positive evidence from randomised trials has been lacking, and the British National Lymphoma Investigation therefore commenced a randomised comparison of CHOP vs a third-generation regimen, PACEBOM, in November 1987. A total of 459 eligible patients were entered into the trial: 226 in the CHOP arm and 233 in the PACEBOM arm. Overall, there was no significant difference in outcome between the two arms of the trial. In patients with stage IV disease there was an apparent improvement in survival for those treated with PACEBOM, but considerable caution must be exercised with such subgroup analysis.

Full text

PDF
318

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cecil J. W., Quagliana J. M., Coltman C. A., Al-Sarraf M., Thigpen T., Groppe C. W., Jr Evaluation of VP-16-213 in malignant lymphoma and melanoma. Cancer Treat Rep. 1978 May;62(5):801–803. [PubMed] [Google Scholar]
  2. De Vita V. T., Jr, Hubbard S. M., Longo D. L. The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987 Nov 15;47(22):5810–5824. [PubMed] [Google Scholar]
  3. Fisher R. I., DeVita V. T., Jr, Hubbard S. M., Longo D. L., Wesley R., Chabner B. A., Young R. C. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med. 1983 Mar;98(3):304–309. doi: 10.7326/0003-4819-98-3-304. [DOI] [PubMed] [Google Scholar]
  4. Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Jr, Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1002–1006. doi: 10.1056/NEJM199304083281404. [DOI] [PubMed] [Google Scholar]
  5. Freedman L. S. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982 Apr-Jun;1(2):121–129. doi: 10.1002/sim.4780010204. [DOI] [PubMed] [Google Scholar]
  6. Goldie J. H., Coldman A. J., Gudauskas G. A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982 Mar;66(3):439–449. [PubMed] [Google Scholar]
  7. Gregory W. M. Adjusting survival curves for imbalances in prognostic factors. Br J Cancer. 1988 Aug;58(2):202–204. doi: 10.1038/bjc.1988.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hryniuk W. M. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988:121–141. [PubMed] [Google Scholar]
  9. Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985 May;102(5):596–602. doi: 10.7326/0003-4819-102-5-596. [DOI] [PubMed] [Google Scholar]
  10. Mathé G., Schwarzenberg L., Pouillart P., Oldham R., Weiner R., Jasmin C., Rosenfeld C., Hayat M., Misset J. L., Musset M. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas. Cancer. 1974 Oct;34(4):985–992. doi: 10.1002/1097-0142(197410)34:4<985::aid-cncr2820340402>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  11. McKelvey E. M., Gottlieb J. A., Wilson H. E., Haut A., Talley R. W., Stephens R., Lane M., Gamble J. F., Jones S. E., Grozea P. N. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976 Oct;38(4):1484–1493. doi: 10.1002/1097-0142(197610)38:4<1484::aid-cncr2820380407>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  12. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shipp M. A., Harrington D. P., Klatt M. M., Jochelson M. S., Pinkus G. S., Marshall J. L., Rosenthal D. S., Skarin A. T., Canellos G. P. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986 Jun;104(6):757–765. doi: 10.7326/0003-4819-104-6-757. [DOI] [PubMed] [Google Scholar]
  14. Sweetenham J. W., Mead G. M., Whitehouse J. M. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma. J Clin Oncol. 1991 Dec;9(12):2202–2209. doi: 10.1200/JCO.1991.9.12.2202. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES